Background: Escitalopram is the active isomer of the antidepressant citalopram. In theory single-isomer drugs may be superior but few have been found to have clinically significant advantages. The manufacturer claims that escitalopram has more efficacy and a faster onset of effect than citalopram. The purpose of this study was to assess how far these claims are justified. Methods: Relevant trial reports were requested from H. Lundbeck A/S and the Swedish drug regulatory authority. The trials consisted of a pooled analysis of 1,321 patients from one unpublished, one partly published and one published eight-week trial, as well as a 24-week trial with 357 patients published as a poster. The studies compared escitalopram with placebo and/or citalopram in outpatients aged ≧18 years who met specified criteria for depression. The trials’ quality was assessed with Moncrieff et al.’s quality assessment instrument and the results compared with the claims from the advertisements. Results: The advertising claims are not justified because they are based on secondary outcomes, non-intention-to-treat analyses and arbitrarily defined subgroups. The subgroup results are inconsistent. Methodological flaws in the trials could account for the differences found. Even if the differences claimed were real they appear too small to justify higher prices. Conclusions: On the evidence available to us the manufacturer’s claims of superiority for escitalopram over citalopram are unwarranted. The Swedish and Danish drug regulatory authorities reached similar conclusions. This highlights the need for wider dissemination of national authorities’ statements to other countries affected by the European Union’s mutual recognition procedure.

Keywords:
Escitalopram, Citalopram, Depression, Advertising, Evidence-based medicine
1.
Tucker GT: Chiral switches. Lancet 2000;355:1085–1087.
2.
Chiral and Fine Chemical Consulting Group: Single enantiomers. Address: http://www.technology-catalysts.com. Accessed: June 20, 2003.
3.
Stinson SC: Chiral pharmaceuticals. Chemical and Engineering News 2001;79:79–91.
4.
Anon: Do Single Stereoisomer Drugs Provide Value? Therapeutics Letter 2002. Address: http://www.ti.ubc.ca/PDF/45.pdf. Accessed: June 20, 2003.
5.
Waugh J, Goa KL: Escitalopram : a review of its use in the management of major depressive and anxiety disorders. CNS Drugs 2003;17:343–362.
6.
H. Lundbeck A/S: Company History: 1990–2000. Address: http://www.lundbeck.com/aboutus/Milestones/1990_2000/. Accessed: June 20, 2003.
7.
H. Lundbeck A/S: Interim report for the first half of 2002. Address: http://www.lundbeck.com/investor/Reportsandpresentations/InterimReports/Interim%20report%20for%20the%20half_year%202002.pdf. Accessed: June 20, 2003.
8.
Läkemedelsverket: Läkemedelsmonografi Cipralex (escitalopram). Address: http://www.mpa.se/mono/cipralex.shtml. Accessed: June 20, 2003.
9.
H. Lundbeck A/S: Halverad dosering ger bättre effekt [Half the dose is more effective]. Marketing material mailed to Swedish physicians, 2002.
10.
Gorman JM, Korotzer A, Su G: Efficacy Comparison of Escitalopram and Citalopram in the Treatment of Major Depressive Disorder: Pooled Analysis of Placebo-Controlled Trials. CNS Spectrums 2002;7(suppl 1):40–44.
11.
H. Lundbeck A/S: Även för patienter med svår depression ger Cipralex bättre effekt än Cipramil [Cipralex is more effective than Cipramil also for patients with severe depression]. Marketing material mailed to Swedish physicians, 2002.
12.
H. Lundbeck A/S: Vecka efter vecka mår patienten bättre och bättre [Week after week the patient feels better and better]. Marketing material mailed to Swedish physicians, 2002.
13.
H. Lundbeck A/S: 99022 Study Summary 28-05-02 QC modified.doc. Trial report, 2002.
14.
H. Lundbeck A/S: Bilden klarnar [The image clears]. Advertisement published in Swedish medical journals, 2003.
15.
Colonna L, Reines EH, Andersen HF: Escitalopram is well tolerated and more efficacious than citalopram in long-term treatment of moderately depressed patients. Presented at Third International Forum on Mood and Anxiety Disorders, November 27–30, 2002, Monte Carlo.
16.
Lægemiddelstyrelsen: Cipralex (escitalopram). Address: http://irf.dk/dk/praeparatnyt/cipralex_escitalopram_02.htm. Accessed: June 20, 2003.
17.
Moncrieff J, Churchill R, Drummond DC, Mcguire H: Development of a quality assessment instrument for trials of treatments for depression and neurosis. Int J Methods Psychiatr Res 2001;10:126–133.
18.
Svensson S: Telephone conversation with Prof. Björn Beermann, Swedish MPA. April 30, 2002.
19.
Burke WJ, Gergel I, Bose A: Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002;63:331–336.
20.
Montgomery SA, Loft H, Sanchez C, Reines EH, Papp M: Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model. Pharmacol Toxicol 2001;88:282–286.
21.
Wade A, Lemming M, Bang Hedegaard K: Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002;17:95–102.
22.
Svensson S: E-mail from Karin Friis Bach, pharmacist, Danish Medicines Agency. September 12, 2002.
23.
Montgomery SA, Åsberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382–389.
24.
Jüni P, Altman DG, Egger M: Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001;323:42–46.
25.
Otto MW, Nierenberg AA: Assay sensitivity, failed clinical trials, and the conduct of science. Psychother Psychosom 2002;71:241–243.
26.
Mazumdar S, Liu KS, Houck PR, Reynolds CF: Intent-to-treat analysis for longitudinal clinical trials: coping with the challenge of missing values. J Psychiatric Research 1999;33:87–95.
27.
Fava M, Evins AE, Dorer DJ, Schoenfeld DA: The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom 2003;72:115–127.
28.
Bland JM, Altman DG: Multiple significance tests: the Bonferroni method. BMJ 1995;310:170.
29.
Demyttenaere K, De Fruyt J: Getting what you ask for: on the selectivity of depression rating scales. Psychother Psychosom 2003;72:61–70.
30.
Müller MJ, Szegedi A, Wetzel H, Benkert O: Moderate and severe depression. Gradations for the Montgomery-Asberg Depression Rating Scale. J Affect Disord 2000;60:137–140.
31.
LINFO Läkemedelsinformation AB: FASS 2003 (Swedish desk reference of drugs). Address: http://www.fass.se. Accessed: June 20, 2003.
32.
Läkemedelsverket: SWEDIS drug database. Accessed: June 20, 2003.
33.
Apoteket AB: Prescription statistics. Accessed: February 12, 2003.
34.
Merriam-Webster Inc: Merriam-Websters Collegiate Dictionary. Address: http://www.merriam-webster.com. Accessed: June 20, 2003.
© 2004 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.